

1 **Mass drug administration to reduce malaria incidence in a low-to-moderate**
2 **endemic setting: short-term impact results from a cluster randomised**
3 **controlled trial in Senegal**

4 **Authors:**

5 El-hadji Ba Konko Ciré, PhD^{1*}, Michelle E. Roh, PhD^{2,3*}, Abdoulaye Diallo, MD¹, Tidiane
6 Gadiaga, MD⁴, Amadou Seck, MS¹, Sylla Thiam, MD¹, Seynabou Gaye, MD⁵, Ibrahima Diallo,
7 PharmD⁵, Aminata Colle Lo, PhD¹, Elhadji Diouf, MPH¹, Omar Gallo Ba, MD¹, Alioune Badara
8 Gueye, MD⁶, Ari Fogelson, MSc⁷, Xue Wu, MMed^{2,3}, Prof Paul Milligan, PhD⁷, Tabitha Kibuka,
9 MPH², Moustapha Hama, MHA², Erin Eckert, PhD², Julie Thwing, MD⁸, Adam Bennett, PhD^{2,9},
10 Prof Roly Gosling, MD^{2,3,10}, Jimee Hwang, MD^{11,12}, Doudou Sene, MD⁵, Fatou Ba, PhD⁵, Bayal
11 Cissé, MD⁴, Katharine Sturm-Ramirez, PhD¹³, Michelle S. Hsiang, MD^{2,3†}, Prof Jean Louis
12 Ndiaye, MD^{1†}

13 **Author Affiliations:**

14 ¹ Université Iba Der Thiam de Thiès, Thiès, Senegal
15 ² US President's Malaria Initiative Impact Malaria, Washington DC, USA
16 ³ Institute for Global Health Sciences, University of California, San Francisco, USA
17 ⁴ District of Tambacounda, Ministry of Health and Social Action, Tambacounda, Senegal
18 ⁵ Senegal National Malaria Control Programme, Ministry of Health and Social Action, Dakar,
19 Senegal
20 ⁶ US President's Malaria Initiative, United States Agency for International Development, Dakar,
21 Senegal
22 ⁷ Department of Infectious Disease Epidemiology, London School of Hygiene and Tropical
23 Medicine, London, UK
24 ⁸ Malaria Branch, US Centers for Disease Control and Prevention, Atlanta, Georgia, USA
25 ⁹ PATH, Seattle, Washington, USA
26 ¹⁰ Department of Disease Control, London School of Hygiene and Tropical Medicine, London
27 UK
28 ¹¹ US President's Malaria Initiative, Malaria Branch, US Centers for Disease Control and
29 Prevention, Atlanta, Georgia, USA
30 ¹² United States Public Health Service, Rockville, MD, USA
31 ¹³ US President's Malaria Initiative, Malaria Branch, US Centers for Disease Control and
32 Prevention, Dakar, Senegal, USA

33 * Contributed equally

34 † Contributed equally

35 **Corresponding authors:**

Michelle E. Roh
UCSF Institute for Global Health Sciences
550 16th Street, 3rd Floor
San Francisco, CA 94158, USA
Email: michelle.roh@ucsf.edu

El-hadji Konko Ciré Ba
Université Iba Der Thiam de Thiès
Grand Standing, Thiès
BP: A967 Thiès
Email: el-hadj.ba@ird.fr

36 **Summary**

37 **Background**

38 In Africa, the scale-up of malaria control interventions, including seasonal malaria
39 chemoprevention (SMC), has dramatically reduced malaria burden, but progress toward malaria
40 elimination has stalled. We evaluated mass drug administration (MDA) as a strategy to
41 accelerate reductions in malaria incidence in Senegal.

42 **Methods**

43 We conducted an open-label, cluster-randomised controlled trial in a low-to-moderate
44 transmission setting of Tambacounda, Senegal. Eligible villages had a population size between
45 200–800. All villages received pyrethroid-piperonyl butoxide bednets and proactive community
46 case management of malaria at baseline. Sixty villages were randomised 1:1 to either three
47 cycles of MDA with dihydroartemisinin-piperaquine+single-low dose primaquine administered
48 to individuals aged ≥ 3 months, six-weeks apart starting the third week of June (intervention), or
49 standard-of-care, which included three monthly cycles of SMC with sulfadoxine-
50 pyrimethamine+amodiaquine administered to children aged 3–120 months starting end of July
51 (control). MDA and SMC were delivered door-to-door. The primary outcome was clinical
52 malaria incidence in all ages assessed during the peak transmission season (July-December), the
53 year after intervention. Here, we report safety, coverage, and impact outcomes during the
54 intervention year. The trial is registered at ClinicalTrials.Gov (NCT04864444).

55 **Findings**

56 Between June 21, 2021 and October 3, 2021, 6505, 7125, and 7250 participants were
57 administered MDA and 3202, 3174, and 3146 participants were administered SMC across
58 cycles. Coverage of ≥ 1 dose of MDA drugs was 79%, 82%, and 83% across cycles. During the
59 transmission season of the intervention year, MDA was associated with a 55% [95% CI: 28%–
60 72%] lower incidence of malaria compared to control (MDA: 93 cases/1000 population; control:
61 173 cases/1000 population). No serious adverse events were reported in either arm.

62 **Interpretation**

63 In low-to-moderate malaria transmission settings with scaled-up malaria control interventions,
64 MDA with dihydroartemisinin-piperaquine+single-low dose primaquine is effective and well-
65 tolerated for reducing malaria incidence. Further analyses will focus on the sustainability of this
66 reduction.

67 **Funding**

68 United States President's Malaria Initiative

69 **Keywords**

70 mass drug administration; seasonal malaria chemoprevention; dihydroartemisinin-piperaquine;
71 primaquine; sulfadoxine-pyrimethamine; amodiaquine; Plasmodium falciparum; malaria;
72 Senegal; transmission

73 **Word Count:** Summary (300); Manuscript (4488)

74 **Research in context**

75 *Evidence before this study*

76 The current World Health Organization (WHO) guidelines recommend that malaria programmes
77 consider mass drug administration (MDA) for *Plasmodium falciparum* transmission reduction in
78 low-to-very low transmission settings (broadly defined as parasite prevalence <10% or annual
79 malaria incidence of <250 cases per population). In moderate-to-high transmission areas, MDA
80 is recommended for rapid reduction of disease burden, but not for transmission reduction due to
81 the lack of published studies demonstrating its short- or long-term benefits. Among the numerous
82 studies that contributed to this recommendation, five evaluated the antimalarial combination,
83 dihydroartemisinin-piperazine + single low-dose primaquine. However, none of the studies
84 were conducted in countries implementing seasonal malaria chemoprevention as part of their
85 routine malaria control strategy.

86 On January 23, 2024, we conducted a PubMed search using the following term: “mass drug
87 administration” AND “dihydroartemisinin-piperazine”. We found one additional cluster
88 randomised controlled trial conducted in a moderate transmission setting of The Gambia (an
89 SMC-implementing country), that evaluated mass drug administration with the antimalarial
90 combination, dihydroartemisinin-piperazine + ivermectin. This study demonstrated that MDA
91 was associated with a 70% reduction in the odds of PCR-confirmed malaria two months after the
92 last round of MDA. However, given the study demonstrated little evidence on entomological
93 outcomes, authors concluded that much of the observed effect of MDA was likely attributable to
94 the antimalarial efficacy of dihydroartemisinin-piperazine.

95 *Added value of this study*

96 Our study adds to the current evidence base demonstrating the benefits of MDA with
97 dihydroartemisinin-piperazine + single-dose primaquine on malaria burden reduction and may
98 have impacts on short-term transmission. Combined with The Gambia trial results, our study
99 provides new evidence demonstrating that MDA with dihydroartemisinin-piperazine can have
100 short-term benefits on transmission in low and moderate transmission settings where malaria
101 transmission is highly seasonal.

102 *Implications of all the available evidence*

103 As countries in sub-Saharan and Sahelian Africa progressively scale-up their malaria control
104 interventions, they will reach a plateau where no further gains can be made. In low and moderate
105 transmission settings, MDA is a well-tolerated and effective intervention for rapidly reducing
106 malaria burden and may have an impact on transmission in the short-term.

107 **Introduction**

108 Malaria is a major public health concern in Africa. In regions where transmission is highly
109 seasonal, seasonal malaria chemoprevention (SMC) has been widely adopted to prevent
110 morbidity and mortality in children at-risk of severe malaria. SMC involves the monthly
111 administration of sulfadoxine-pyrimethamine + amodiaquine given during the peak transmission
112 season to treat existing parasitaemia and prevent new infections.¹ Since its initial
113 recommendation by the World Health Organisation (WHO) in 2012, SMC has expanded to 18
114 African countries, covering 53 million children in 2023.² The scale-up of SMC has been
115 successful, demonstrating reductions in childhood clinical malaria incidence by 60–88% under
116 programmatic conditions.^{1,3}

117 Through high coverage of SMC, strong vector control, and prompt case management, countries
118 in Sahelian and sub-Saharan Africa have made significant strides in controlling malaria,
119 prompting many to establish new goals for malaria elimination. However, recent progress toward
120 elimination has stalled,⁴ necessitating enhanced coverage of proven core interventions and the
121 consideration of new interventions to rapidly reduce transmission. One promising approach is
122 mass drug administration (MDA), which involves the administration of antimalarials to all
123 individuals in a defined geographic area at a frequency and duration tailored to the local malaria
124 epidemiology and goals. For MDA to have an impact on transmission, high coverage ($\geq 80\%$)^{5,6}
125 of the target population is needed, which requires an optimized delivery approach and strong
126 community engagement.⁷ Achieving high coverage may be less challenging in countries
127 successfully implementing SMC, as they can leverage their existing infrastructure of door-to-
128 door delivery and community and health system acceptance of chemoprevention.^{8,9}

129 In addition to attaining high coverage, the effectiveness of MDA depends on the type of
130 antimalarial regimen used. In *Plasmodium falciparum*-dominant regions, dihydroartemisinin-
131 piperaquine is an attractive agent for MDA given its good safety profile, long prophylactic
132 period, and relatively low-levels of artemisinin resistance in Africa.^{10,11} However,
133 dihydroartemisinin-piperaquine has no known efficacy against mature gametocytes^{12,13}—the
134 parasites responsible for human-to-mosquito transmission. Single low-dose primaquine is a
135 gametocytocidal agent shown to be safe and associated with the near complete prevention of
136 human-to-mosquito transmission.^{14,15} It is likely that the combination of these drugs may confer
137 greater benefits than dihydroartemisinin-piperaquine alone, allowing MDA to have a greater
138 impact on transmission.

139 Here, we present results from a cluster randomised controlled trial assessing the safety, coverage,
140 and short-term impact of three cycles of MDA with dihydroartemisinin-piperaquine + single
141 low-dose primaquine on *P. falciparum* incidence and prevalence during the intervention year.
142 This study aimed to fill a critical evidence gap regarding the effectiveness of MDA to rapidly
143 reduce malaria burden in a highly seasonal, low-to-moderate transmission setting where malaria
144 control measures have been scaled-up and additional interventions are needed to accelerate
145 malaria elimination.

146 **Methods**

147 *Study setting*

148 The study was conducted in Tambacounda Health District of southeastern Senegal (**Appendix**
149 **1**). The district is comprised of 523 villages with an estimated population size of 297,761 in
150 2020. In southeastern Senegal, malaria transmission is low-to-moderate (50–200 cases per 1000
151 population) and highly seasonal, with most cases occurring between July and December. In this
152 region, the national malaria programme (*Programme National de Lutte contre le Paludisme*;
153 PNLP) implements standard malaria control interventions including routine distribution of
154 insecticide-treated nets, malaria case management at health facilities, SMC to children 3–120
155 months of age (except those with a severe/chronic illness, known hypersensitivity to SMC drugs,
156 and history of antimalarial receipt in the prior three weeks), and proactive community case
157 management of fever through the *Prise en Charge à Domicile Plus* (PECADOM+) model. In the
158 PECADOM+ model, community health workers, known as dispensateur de soins à domiciles
159 (DSDOMs), conduct weekly household visits to identify and treat suspected malaria cases during
160 the malaria transmission season. Despite scale-up of these interventions, progress toward
161 transitioning these zones to pre-elimination status has been slow. Thus, in these areas, the
162 program needs an accelerator intervention to aggressively push the elimination margins and meet
163 the national goal to eliminate malaria by 2030.

164 *Study design and participants*

165 The study employed a two-arm, open-label, cluster randomised controlled trial design. Sixty
166 villages were randomly selected for participation. Villages were eligible if they had a population
167 size between 200–800; were located within a health post catchment area with an annual malaria
168 incidence of 60–160 cases/1000 population; and had an established PECADOM+ system or the
169 PEACDOM+ model was planned for implementation in the village. Villages were selected so
170 that village centroids were ≥ 2.5 km apart.

171 Participant eligibility was assessed prior to each MDA cycle. Residents of intervention villages
172 were eligible for MDA if they were ≥ 3 months of age and excluded if they reported a
173 severe/chronic illness, had a known hypersensitivity to study drugs, were pregnant (confirmed by
174 urine test), had taken drugs that could influence cardiac function or prolong QTc interval, or
175 received antimalarials in the prior three weeks. Children < 2 years of age and breastfeeding
176 women were further excluded from receiving single low-dose primaquine. No SMC was
177 provided during the intervention year in intervention villages.

178 Written informed consent was obtained before the first MDA cycle and cross-sectional surveys.
179 Parental written informed consent was obtained from participants < 18 years of age and written
180 informed assent was obtained from children 13–17 years of age.

181 Ethical approval of this trial was granted by the Comité National d’Ethique pour la Recherche en
182 Santé (CNERS) of Senegal and the University of California, San Francisco (UCSF) Human
183 Research Protection Program. The U.S. Centers for Disease Control and Prevention approved
184 reliance on UCSF. The trial was registered with ClinicalTrials.gov (NCT04864444) and
185 oversight was provided by an independent data safety monitoring committee and external
186 monitor. An interim safety analysis was conducted after the first MDA cycle.

187 *Randomisation and masking*

188 Study villages were randomised 1:1 to intervention or control. To ensure adequate balance with
189 respect to specified variables, villages were stratified based on whether PECADOM+ was
190 present at baseline. Then a constrained randomisation approach was undertaken using the
191 following village-level covariates: health post of village, distance to health post, baseline malaria
192 prevalence (assessed through a survey conducted at the end of the pre-intervention transmission
193 season), village population size, and population size of children <10 years. A study investigator
194 (MER) randomly generated intervention assignment. Participants, field team, and investigators
195 were unblinded to allocation assignment. Laboratory technicians were blinded to intervention
196 assignment.

197 *Procedures*

198 *Community mobilisation and sensitisation*

199 Upon village selection, the study team held meetings with administrative, health, and religious
200 leaders of Tambacounda Health District to discuss the study aims, planned activities, and receive
201 consent for study implementation. Community sensitisation materials were developed by the
202 study team and implemented by local health staff. In the months prior to MDA, which coincided
203 with the peak COVID-19 pandemic, additional social media campaigns, local community radio
204 announcements, and television advertisements were conducted. Prior to each MDA cycle, town
205 hall meetings and household visits were undertaken to ensure that the community was well-
206 informed.

207 *Interventions*

208 In the control arm, the standard-of-care chemoprevention (which consisted of three cycles of
209 SMC with sulfadoxine-pyrimethamine + amodiaquine) was administered to children aged 3-120
210 months at four-week intervals, initiated at the presumed start of the malaria transmission season.
211 In the intervention arm, three cycles of MDA with dihydroartemisinin-piperaquine + single low-
212 dose primaquine were administered to individuals aged ≥ 3 months at six-week intervals. To
213 achieve maximal impact on clearing the infectious reservoir,^{16,17} MDA was initiated one month
214 prior to the presumed start of the transmission season (**Figure 1**). Prior to intervention
215 implementation, pyrethroid-piperonyl butoxide (PBO) bednets were distributed door-to-door to
216 all study villages and year-round PECADOM+ was established to monitor malaria incidence.

217 MDA and SMC were delivered door-to-door by DSDOMs via directly observed therapy for all
218 three doses. Study drugs were administered using an age-based dosing strategy per
219 manufacturer's instructions (**Appendix 2**). For each MDA cycle, dihydroartemisinin-piperaquine
220 (Eurartesim™, Sigma-Tau, Italy) was given for three consecutive days and single low-dose
221 primaquine (Remedica Ltd, Limassol, Cyprus) was given with the first dose of
222 dihydroartemisinin-piperaquine. For each SMC cycle, amodiaquine (Fosun Pharma, Shanghai,
223 China) was given for three consecutive days and sulfadoxine-pyrimethamine (Fosun Pharma,
224 Shanghai, China) was given with the first dose of amodiaquine. For participants who were

225 unable to swallow tablets (e.g., young children), tablets were crushed and mixed in water. If the
226 participant vomited within 30 minutes of administration, the full dose was re-administered. If the
227 re-administered dose was vomited within 30–60 minutes, half the dose was administered.

228 During drug administration, individuals with symptomatic malaria confirmed by a histidine-rich
229 protein 2-based rapid diagnostic test (RDT) (ParaHIT®-f, ARKRAY Healthcare Pvt Ltd, Surat,
230 India) were treated with artemether-lumefantrine and did not receive study drugs until the
231 subsequent cycle.

232 *Malaria surveillance*

233 Malaria cases were captured through health facility and PECADOM+ registries. Suspected cases
234 (i.e., presentation of fever or history of fever in the past 48 hours) were confirmed by RDT. To
235 ensure high-quality capture of incident cases, PECADOM+ was expanded year-round
236 implementation in all study villages and fully scaled-up by March 1, 2021. Data were collected
237 on paper-based registries and abstracted onto electronic databases. Duplicates between registries
238 were removed. Village-level population size was estimated by averaging estimates from two
239 censuses conducted before-and-after intervention implementation (**Figure 1**).

240 *Pharmacovigilance*

241 Passive and active pharmacovigilance systems were used to monitor the safety of MDA. For
242 passive surveillance, adverse events (AEs) following drug intake were recorded by study staff or
243 DSDOMs into standardised case report forms. Participants were encouraged to inform local
244 health or study staff if they experienced an AE within one month after drug intake. AEs were
245 graded by a study clinician (e.g., mild, moderate, or severe) and managed free of charge. For
246 active surveillance monitoring, the study staff surveyed 220 random households per study arm on
247 the day after the last dose of study drugs. Households were sampled from every village,
248 proportionate to village population size, such that five households were sampled from villages
249 with <300 residents and ten households from villages with ≥ 300 residents. In intervention
250 villages, the study team randomly sampled three members per household according to their age
251 group: <5, 5–15, and ≥ 15 years. In control villages, three household members <10 years of age
252 were randomly sampled. Survey participants were asked if they experienced an AE and to
253 describe the event, including type, onset date, and duration. Severity was graded by a study
254 clinician.

255 *Cross-sectional surveys*

256 To determine parasite prevalence, cross-sectional surveys were conducted at the end of the
257 transmission season before-and-after intervention implementation (December 10–20, 2020 and
258 December 9–21, 2021). A two-stage cluster sampling strategy was undertaken to randomly select
259 households and household members from all villages. Participants were asked about their
260 demographic characteristics, malaria prevention measures, and history of fever. Suspected
261 malaria cases were confirmed by RDT and those with a positive test were treated with
262 artemether-lumefantrine. A fingerprick blood sample was taken for microscopy and for dried
263 blood spots (DBS) to confirm parasitaemia by PCR and to genotype drug resistance markers.

264 *Laboratory analysis*

265 Microscopy slides and DBS from surveys were transported to Université Iba Der Thiam de
266 Thiès. Slides were stained with 6% Giemsa for 20 min and read by two microscopists. A third
267 reviewer settled discrepant findings. Parasite DNA was extracted from DBS using the Chelex-
268 100 extraction method¹⁸ and tested for parasitemia by real-time PCR using species-specific
269 primers based on 18S rRNA gene as previously described.¹⁹ PCR-positive samples were
270 genotyped to assess the presence of point mutations in the *pfK13*, *pfdhps*, *pfdhfr*, *pfcr*, and
271 *pfmdr1* genes using high-resolution melting analysis as previously described.²⁰

272 *Study outcomes*

273 The primary outcome of the trial was village-level malaria incidence in the year after
274 intervention implementation. Here, we report the impact of MDA on incidence during the
275 transmission season of the implementation year. Village-level malaria incidence was defined as
276 the number of RDT-confirmed symptomatic malaria cases detected through health post and
277 PECADOM+ surveillance divided by the average village population size obtained from two
278 censuses performed before-and-after intervention implementation (**Figure 1**). Secondary
279 outcomes included parasite prevalence by microscopy and PCR, coverage and safety of MDA,
280 and prevalence of drug resistance markers assessed through cross-sectional surveys.

281 Coverage was defined according to WHO guidelines⁷. For each chemoprevention campaign, a
282 pre-intervention census was used to generate a registry that determined who would be targeted
283 for each cycle. Data on adherence and dose were recorded for each person and day. The registry
284 was updated throughout the campaign to identify new residents, deaths, and emigrants. Both
285 crude and distributional coverage are reported. Crude coverage was defined as the proportion of
286 residents who received ≥ 1 dose of study drugs among study residents. Denominator included
287 absences, refusals, and those who did not meet the eligibility criteria. Distribution coverage was
288 defined as the proportion of residents who received ≥ 1 dose among eligible residents, thereby
289 excluding pregnant women and those with a self-reported illness. Both coverage metrics
290 excluded deaths and emigrants.

291 *Statistical analysis*

292 All analyses were conducted using Stata version 17.0 or R version 4.2.2. Sample size
293 calculations were based on detecting a 50% relative difference in RDT-confirmed malaria
294 incidence between arms in the year post-intervention. We assumed mass distribution of
295 pyrethroid-PBO bednets, SMC, and scale-up of community case management would
296 cumulatively reduce annual malaria incidence by 50% in the control arm from 100 to 50
297 cases/1000 population before-and-after intervention implementation. Based on a coefficient of
298 variation of 0.80 and an average cluster size of 250, a sample size of 60 clusters provided 80%
299 power (using a 5% significance level) to detect a 50% relative difference in the MDA arm
300 (intervention effect) using a two-tailed alpha test.

301 Analyses were carried out using an intention-to-treat approach. Intervention impact on incidence
302 was assessed using mixed-effects Poisson regression with village-level random intercepts. In the
303 unadjusted model, the following indicator variables were included: a treatment indicator that
304 equalled 1 in intervention villages during the implementation year and 0 otherwise and a time
305 variable that equalled 1 during the implementation year and 0 otherwise. Adjusted analyses
306 included covariates used in the stratified constrained randomization scheme. Intervention impact
307 was defined as the percent reduction in incidence between July and December in the intervention
308 arm compared to the control arm ($1 - \text{incidence rate ratio (IRR)}_{\text{intervention}} * 100\%$). Intervention
309 effects on parasite prevalence were estimated using Poisson regression with robust standard
310 errors. Survey weights accounting for number of households and household size were
311 incorporated into prevalence analyses. Prespecified subgroup analyses were conducted by age
312 group (e.g., \geq or <10 years of age), DSDOM presence at baseline, and baseline transmission
313 intensity (low versus moderate; low defined as parasite prevalence $<10\%$ as defined by WHO¹)
314 using two-way interaction terms between treatment and subgroup variables.

315 **Results**

316 Between September 1, 2020 and October 25, 2020, 523 villages in the study area were
317 geolocated and screened for eligibility, and 111 met the inclusion criteria (**Figure 2**). Of these,
318 60 villages were randomly selected allowing for a ≥ 2.5 km distance between village centroids
319 and randomised to intervention or control. Village-level factors included in the constrained
320 randomisation were balanced across arms (**Table 1**). Overall, coverage of pyrethroid-PBO
321 bednets was high (98%) and similar between arms. In the pre-intervention year, 81% of children
322 <10 years of age reported receiving the most recent cycle of SMC and 71% reported receiving all
323 three cycles. Twenty percent reported sleeping away from their home in the past 15 days.

324 In the intervention arm, 8931, 9571, and 9703 residents were screened for the first, second, and
325 third cycle of the MDA campaign. Distribution coverage of single low-dose primaquine (where
326 the denominator excluded ineligible residents) was 79% (6286/7992), 82% (6949/8462), and
327 84% (7199/8575) across the three cycles. Distribution coverage of ≥ 1 dose of
328 dihydroartemisinin-piperaquine among the eligible individuals was 79% (6505/8229), 82%
329 (7125/8673), and 83% (7250/8690) in the first, second, and third cycles. Distribution coverage of
330 all three doses of dihydroartemisinin-piperaquine was 74%, 79%, and 81% across cycles.
331 Distribution coverage was higher in those <10 years compared to ≥ 10 years (distribution
332 coverage of ≥ 1 dose was 85%, 86%, and 87% in <10 years across cycles, and 75%, 80%, and
333 81% in ≥ 10 years across cycles). Crude coverage of ≥ 1 dose of dihydroartemisinin-piperaquine
334 was 73%, 74%, and 75% across cycles. By village, distribution coverage ranged from 58%–97%;
335 50%, 67%, and 70% of intervention villages reached the WHO target coverage of $\geq 80\%$ in the
336 first, second, and third cycles, respectively (**Appendix 3**). The major reasons for non-
337 participation were absence (range: 14%–21%) and illness (range: 5%–7%) (**Appendix 4**).
338 Absences were similar between males and females (1·12:1 ratio) and in age to those who
339 received MDA (16 years [interquartile range (IQR): 7–26] versus 13 years [IQR: 6–27]).
340 Refusals were rare (1%–2%) and mostly among males (70%) with a median age of 22 years
341 [IQR: 15–30].

342 In the control arm, 3492, 3489, and 3487 children aged 3–120 months were screened for the first,
343 second, and third SMC cycle. Distribution coverage of ≥ 1 dose of SMC drugs was 93%
344 (3202/3457), 92% (3174/3442), and 92% (3146/3434) across cycles. Distribution coverage for
345 all three SMC doses was 92%, 92%, and 91% across cycles. Crude coverage of ≥ 1 dose was
346 92%, 91%, and 90% across cycles. By village, distribution coverage ranged from 62%–100%;
347 93% of SMC villages reached $\geq 80\%$ coverage across all cycles (**Appendix 3**). Major reasons for
348 non-receipt of SMC were absence (7%) and illness (1%–2%) (**Appendix 4**). Refusals of SMC
349 were low across cycles ($\leq 1\%$).

350 During the pre-intervention transmission season (July–December 2020), malaria incidence was
351 181 and 204 cases/1000 population in the intervention and control arms, respectively (**Table 2**).
352 In the transmission season of the intervention year (July–December 2021), malaria incidence
353 reduced to 93 cases/1000 population in the intervention arm and to 173 cases/1000 population in
354 the control arm (**Table 2; Figure 3**). The unadjusted intervention effect of MDA was 52% [95%
355 CI: 21%, 71%]. The adjusted intervention effect, which accounted for variables included in the
356 constrained randomisation was 55% [95% CI: 28%, 72%].

357 Pre-specified subgroup analyses showed evidence of an interaction by age group; the adjusted
358 intervention effect was 58% [95% CI: 33%, 74%] in the ≥ 10 years age group and 46% [95% CI:
359 10%, 67%] in the < 10 years age group ($p_{\text{interaction}}=0.016$) (**Table 2; Figure 3**). The impact of
360 MDA on malaria incidence was similar in low and moderate transmission settings defined as
361 microscopy parasite prevalence of $< 10\%$ versus $\geq 10\%$ (adjusted intervention effect=55% [31%,
362 71%] versus 52% [-19%, 81%]; $p_{\text{interaction}}=0.88$) (**Table 2; Figure 3**).

363 By microscopy, parasite prevalence decreased between 2020 and 2021, from 6.1% to 1.8% in the
364 intervention arm and from 6.7% to 4.7% in the control arm (adjusted intervention effect=62%
365 [95% CI: 22%, 80%]) (**Table 3**). The impact of MDA differed between the < 10 and ≥ 10 years
366 age group (adjusted intervention effect=76% [95% CI: 42%, 90%] versus 51% [95% CI: -14%,
367 79%]), but this finding did not reach statistical significance ($p_{\text{interaction}}=0.17$). By PCR, parasite
368 prevalence decreased between 2020 and 2021, from 17.9% to 4.5% in the intervention arm and
369 19.9% to 8.3% in the control arm (adjusted intervention effect=47% [95% CI: 3%, 71%]). The
370 effect of MDA differed between the < 10 and ≥ 10 years age groups: adjusted intervention
371 effect=71% [95% CI: 35%, 87%] and 33% [95% CI: -27%, 65%], respectively ($p_{\text{interaction}}=0.050$).
372 The impact of MDA on microscopy- or PCR-confirmed parasite prevalence did not significantly
373 differ between low and moderate transmission settings ($p_{\text{interaction}}$ for microscopy-confirmed
374 prevalence=0.73, $p_{\text{interaction}}$ for PCR-confirmed prevalence=0.73) (**Table 3**).

375 In both passive and active pharmacovigilance systems, the frequency of AEs reduced with each
376 subsequent cycle and no serious adverse events (SAEs) were detected in either arm (**Appendix**
377 **5; Table 4**). Through passive surveillance, 129 AEs were observed in 67/20 887 (0.003%)
378 participants of the intervention arm and four AEs were observed in 2/9524 (0.0002%)
379 participants of the control arm; all were mild (**Appendix 5**). Both the frequency and proportion
380 of participants who experienced an AE were higher in the intervention arm compared to the
381 control arm ($p < 0.0001$). The most common AEs found in the intervention arm were
382 gastrointestinal issues (45.7%), headaches (25.6%), and fever (17.1%).

383 Through active surveillance, more participants of the intervention arm reported an AE compared
384 to the control arm (13.7% versus 9.4%; $p < 0.0001$) (**Table 4**). Among children aged < 10 years,
385 the proportion of reported AEs were similar between arms (10.1% versus 9.4%; $p = 0.57$). In the
386 intervention arm, the most common AEs were gastrointestinal issues (41.2%), fever (22.7%), and
387 headaches (11.8%). Of the 498 AEs reported in the intervention arm, 64.1% were mild, 32.9%
388 were moderate, and 3.0% were severe. Severe AEs included fever ($n = 7$), headache ($n = 4$),
389 drowsiness ($n = 1$), vomiting ($n = 1$), diarrhoea ($n = 1$), and loss of appetite ($n = 1$). All AEs appeared
390 three hours after drug intake, resolved within 72 hours, and did not require hospitalization. No
391 cases of anaemia were found through either passive or active surveillance.

392 Of the 597 PCR-positive samples collected from surveys, 433 were successfully genotyped to
393 determine molecular markers of antimalarial resistance (**Appendix 6**). Mutations associated with
394 intermediate resistance to SP (PfDHFR N51I, C59R, S108N and PfDHPS A437G) were seen at
395 high proportions (range: 58%–100%). PfDHFR I164L was seen at proportions of 2%–12%.
396 None of the studied mutations differed in proportions between arms or time periods. There was
397 no evidence of PfDHPS K540E, PfDHPS A581G, or PfK13 C580Y mutations.

398 **Discussion**

399 We conducted a cluster randomised controlled trial evaluating the safety, coverage, and short-
400 term effectiveness of three rounds of MDA with dihydroartemisinin-piperazine + single low-
401 dose primaquine in a low-to-moderate transmission setting of Senegal where malaria control
402 interventions were scaled-up through pyrethroid-PBO bednet distribution, three monthly SMC
403 cycles, and expansion of year-round proactive community case management of malaria. During
404 the trial intervention year, malaria incidence and parasite prevalence reduced in both arms, likely
405 due in part to pyrethroid-PBO bednet distribution. In intervention villages, MDA was associated
406 with a 55% and 62% reduction in malaria incidence and microscopy-confirmed parasite
407 prevalence. Subgroup analyses showed that MDA had a substantial impact on incidence and
408 parasite prevalence in those < 10 and ≥ 10 years of age and in both low and moderate transmission
409 settings. Overall, MDA was well-tolerated; most AEs were mild or moderate and no cases of
410 anaemia or SAEs were observed.

411 While the trial was not designed to separately estimate MDA's effect on transmission versus its
412 direct, prophylactic effect, there was some evidence to suggest that MDA indirectly affected
413 transmission. First, subgroup analyses demonstrated that among children under ten, MDA was
414 associated with a 46% reduction in incidence as compared to children under ten in the control
415 arm who received SMC. We expect that this reduction is unlikely by differences in the
416 prophylactic effects of these drugs given we expect dihydroartemisinin-piperazine and
417 sulfadoxine-pyrimethamine + amodiaquine to have similar protective efficacies,¹¹ MDA covered
418 less of the transmission season, and MDA had slightly lower coverage than SMC in under tens.
419 Moreover, MDA's impact on parasite prevalence further supports this reasoning, given the
420 endline survey was conducted more than two months after the last cycle of drug administration
421 when the prophylactic effects of both MDA and SMC drugs would have waned.

422 Our study has several important findings/caveats. First, our monthly incidence analyses (**Figure**
423 **4**) revealed that SMC should have started one month later and both chemoprevention campaigns

424 should have been extended to four cycles to cover the entire transmission season. If this had this
425 been done, the impact of MDA in children under tens might not have been as substantial.
426 Second, our findings may not be generalisable to most settings deploying SMC where the
427 malaria burden is mostly moderate-to-high. While our study found MDA was associated with
428 reductions in malaria burden and short-term transmission, evidence of its sustained benefit and
429 cost-effectiveness is needed before considering MDA as an intermediate intervention to
430 accelerate malaria elimination.

431 The WHO currently recommends MDA for transmission reduction in very low-to-low
432 transmission settings (i.e., parasite prevalence of <10% or incidence <250 cases/1000
433 population). This recommendation is based on evidence from eight cluster randomised controlled
434 trials which found MDA can have a substantial, but short-term impact in these settings.^{1,21,22}
435 However, MDA is not recommended for transmission reduction in moderate-to-high
436 transmission settings, based on evidence from two cluster randomised trials and two non-
437 randomized studies which did not show significant short- or long-term impacts on prevalence or
438 incidence. Our study provides new evidence indicating MDA may have a short-term impact on
439 transmission in both low and moderate transmission strata. Our findings are consistent with a
440 recent trial conducted in a moderate transmission setting of The Gambia²³ which demonstrated a
441 70% reduction in the odds of PCR-confirmed infection two months after the last MDA cycle.
442 Evidence from these two studies should be considered when determining future
443 recommendations in moderate transmission settings.

444 There were several strengths of the study, including our large sample size, rigorous monitoring
445 of safety, and achievement of high coverage. By the final MDA cycle, 70% (21/30) of villages
446 reached the WHO target for MDA coverage ($\geq 80\%$)⁷, despite significant operational challenges
447 in door-to-door drug administration amidst the peak of the global COVID-19 pandemic. The
448 high coverage observed in our study was likely attributable to community acceptance of annual
449 SMC campaigns, established infrastructure of community case management, support from key
450 administrative and health authorities, and repeated community sensitisation campaigns.
451 However, absences were common during MDA cycles (14-21%), especially among adolescents
452 and young adults who are generally asymptomatic and known to be important drivers of
453 transmission.²⁴ Thus, in order to sustain gains made, future MDA campaigns will need to
454 consider additional strategies to reach these groups in order to prevent malaria importation and
455 potential resurgence after MDA.

456 Our study had a few limitations. First, as explained earlier, SMC was not optimally timed,
457 making it difficult to draw direct comparisons between SMC and MDA for burden reduction in
458 children. Second, baseline incidence was likely non-differentially mismeasured in villages where
459 DSDOMs were absent at the start of the study (33% of villages). While the stratified
460 randomization scheme balanced this factor between arms, this may have biased our effect
461 estimates toward the null (see **Appendix 7** for analyses restricted to villages with prior
462 PECADOM+). Third, given baseline incidence was likely mismeasured, subgroup analyses by
463 baseline malaria incidence were not reported. Fourth, parasitological confirmation of malaria
464 incidence relied on RDT which could have resulted in false positives potentially biasing our
465 effect estimates toward the null. Fifth, MDA was conducted for only one year and additional
466 cycles may have been needed to reach pre-elimination status (i.e., incidence <5 cases/1000

467 population). Finally, the current analyses only evaluated short-term impact. After discontinuation
468 of MDA, there is potential for malaria to rebound, and analyses of longer-term impact and cost-
469 effectiveness from an additional year of follow-up of these cohorts are forthcoming which will
470 help to determine the sustainability of MDA.

471 In low-to-moderate malaria transmission settings, where transmission is seasonal and coverage
472 of standard malaria control interventions is high, we demonstrated that three cycles of MDA with
473 dihydroartemisinin-piperaquine + single-low dose primaquine could safely and rapidly reduce
474 malaria burden and potentially have a short-term impact on transmission. However, future work
475 investigating whether the impact of MDA can be sustained, and its cost-effectiveness is needed
476 to inform countries of the potential of MDA as an intervention to accelerate toward elimination.

477 **Role of the funding source**

478 The study was funded under the US President's Malaria Initiative Impact Malaria Consortium.
479 The funders participated in the design of the study and reviewed the manuscript prior to
480 submission. The funders had no role in data collection and data analysis. The first authors had
481 full access to the study data and final responsibility for the decision to submit the manuscript.

482 **Acknowledgements**

483 We are grateful to the community of Tambacounda Health District for their participation in the
484 study. We thank the health workers, district health staff, the PNL, and research team at
485 Université Iba Der Thiam de Thiès for their contributions in implementing the study and to PMI
486 Vectorlink for conducting pyrethroid-PBO bednet distribution and the early village population
487 census. We also thank our data safety and monitoring board members Prof Umberto
488 D'Alessandro (chair), Prof Jean Guadart, Prof Menno R Smit, Dr Houda Sefiani, and Dr Thomas
489 J Peto for their guidance and oversight of the study. We would also like to thank Drs Meera
490 Venkatesan, Meghna Desai, and Leah Moriarty for their contributions in the early protocol
491 development and study planning, Dr Mame Birame Diouf for his initial coordination and
492 strategic engagement of in-country partners, Drs Jean Biyik and Abdoulaye Diop for their
493 support in coordinating the pyrethroid-PBO bednet distribution, and Dr Hannah Slater for
494 providing the mathematical modelling analysis used for our sample size calculations.

495 **Contributions**

496 JH conceived of the study and wrote the first draft of the protocol. RG, JLN, MER, AB, KSR,
497 JT, EBKC, FB, ST, ID, and ABG contributed to the protocol and approved of the final version.
498 EBKC, AD, TG, AS, ST, SG, ACL, ED, ID, OGB, and JLN implemented the study. JLN,
499 EBKC, AD, TG, ABG, ST, KSR, MER, MSH, TK, MH, EE, RG, DS, and FB provided
500 oversight of the study. ACL conducted laboratory analysis of samples. The statistical analysis
501 plan was developed by MSH, PM, AF, MER, AB, EBKC, and JLN and data were analysed by
502 AF with XW, MER, AS, and EBKC. MER, EBKC, AF, XW, PM, AB, JH, KSR, MSH, and JLN
503 interpreted the results. MER, EBKC, MSH, and JLN wrote the first draft of the manuscript. PM,
504 JH, AF, and KSR provided additional inputs to the writing. All authors reviewed and approved
505 the final manuscript before submission.

506 **Declaration of interests**

507 The study was funded by the US President's Malaria Initiative. MER is supported by the Eunice
508 Kennedy Shriver National Institute of Child Health & Human Development of the National
509 Institutes of Health (Award Number K99HD111572). JH and ABG receive salary support from
510 the US President's Malaria Initiative. The findings and conclusions in this report are those of the
511 authors and do not necessarily represent the official position of the National Institutes of Health,
512 US Centers of Disease Control and Prevention, and the US Agency for International
513 Development.

514 **Data sharing**

515 De-identified data may be available upon reasonable request and approval from Principal
516 Investigators via a data sharing agreement.


517 **References**

- 518 1. World Health Organization. WHO guidelines for malaria, 3 June 2022: World Health
519 Organization, 2022.
- 520 2. SMC Alliance. 53 million children living in 18 countries covered with Seasonal Malaria
521 Chemoprevention in 2023. April 5, 2024 2024. [https://www.smc-alliance.org/53-million-](https://www.smc-alliance.org/53-million-children-living-in-18-countries-covered-with-seasonal-malaria-chemoprevention-in-2023)
522 [children-living-in-18-countries-covered-with-seasonal-malaria-chemoprevention-in-2023](https://www.smc-alliance.org/53-million-children-living-in-18-countries-covered-with-seasonal-malaria-chemoprevention-in-2023)
523 (accessed July 17, 2024).
- 524 3. Cairns M, Ceesay SJ, Sagara I, et al. Effectiveness of seasonal malaria chemoprevention
525 (SMC) treatments when SMC is implemented at scale: Case–control studies in 5 countries. *PLoS*
526 *Med* 2021; **18**(9): e1003727.
- 527 4. World Health Organization. World Malaria Report 2022. Geneva, Switzerland: World
528 Health Organization; 2022.
- 529 5. Newby G, Hwang J, Koita K, et al. Review of mass drug administration for malaria and
530 its operational challenges. *Am J Trop Med* 2015; **93**(1): 125.
- 531 6. Shah MP, Hwang J, Choi L, Lindblade KA, Kachur SP, Desai M. Mass drug
532 administration for malaria. *The Cochrane Database of Systematic Reviews* 2021; **2021**(9).
- 533 7. World Health Organization. Mass drug administration for falciparum malaria: a practical
534 field manual. 2017.
- 535 8. Cairns ME, Sagara I, Zongo I, et al. Evaluation of seasonal malaria chemoprevention in
536 two areas of intense seasonal malaria transmission: secondary analysis of a household-
537 randomised, placebo-controlled trial in Houndé District, Burkina Faso and Bougouni District,
538 Mali. *PLoS Med* 2020; **17**(8): e1003214.
- 539 9. NDiaye J, Cissé B, Ba E, et al. Safety of seasonal malaria chemoprevention (SMC) with
540 sulfadoxine-pyrimethamine plus amodiaquine when delivered to children under 10 years of age
541 by district health services in Senegal: results from a stepped-wedge cluster randomized trial.
542 *PLoS One* 2016; **11**(10): e0162563.
- 543 10. Gutman J, Kovacs S, Dorsey G, Stergachis A, Ter Kuile FO. Safety, tolerability, and
544 efficacy of repeated doses of dihydroartemisinin-piperaquine for prevention and treatment of
545 malaria: a systematic review and meta-analysis. *Lancet Infect Dis* 2017; **17**(2): 184-93.
- 546 11. Zongo I, Milligan P, Compaore YD, et al. Randomized noninferiority trial of
547 dihydroartemisinin-piperaquine compared with sulfadoxine-pyrimethamine plus amodiaquine for
548 seasonal malaria chemoprevention in Burkina Faso. *Antimicrob Agents Chemother* 2015; **59**(8):
549 4387-96.
- 550 12. Dicko A, Roh ME, Diawara H, et al. Efficacy and safety of primaquine and methylene
551 blue for prevention of Plasmodium falciparum transmission in Mali: a phase 2, single-blind,
552 randomised controlled trial. *Lancet Infect Dis* 2018; **18**(6): 627-39.
- 553 13. Sawa P, Shekalaghe SA, Drakeley CJ, et al. Malaria transmission after artemether-
554 lumefantrine and dihydroartemisinin-piperaquine: a randomized trial. *J Infect Dis* 2013; **207**(11):
555 1637-45.
- 556 14. World Health Organization. Policy brief on single-dose primaquine as a gametocytocide
557 in Plasmodium falciparum malaria: World Health Organization, 2015.
- 558 15. Stepniewska K, Humphreys GS, Gonçalves BP, et al. Efficacy of single-dose primaquine
559 with artemisinin combination therapy on Plasmodium falciparum gametocytes and transmission:
560 an individual patient meta-analysis. *J Infect Dis* 2022; **225**(7): 1215-26.

- 561 16. Eisele TP, Bennett A, Silumbe K, et al. Short-term impact of mass drug administration
562 with dihydroartemisinin plus piperaquine on malaria in Southern Province Zambia: a cluster-
563 randomized controlled trial. *J Infect Dis* 2016; **214**(12): 1831-9.
- 564 17. Griffin JT. The interaction between seasonality and pulsed interventions against malaria
565 in their effects on the reproduction number. *PLoS Comput Biol* 2015; **11**(1): e1004057.
- 566 18. Amoah LE, Opong A, Ayanful-Torgby R, Abankwa J, Acquah FK. Prevalence of G6PD
567 deficiency and Plasmodium falciparum parasites in asymptomatic school children living in
568 southern Ghana. *Malar J* 2016; **15**(1): 1-8.
- 569 19. Rougemont M, Van Saanen M, Sahli R, Hinrikson HP, Bille J, Jatou K. Detection of four
570 Plasmodium species in blood from humans by 18S rRNA gene subunit-based and species-
571 specific real-time PCR assays. *J Clin Microbiol* 2004; **42**(12): 5636-43.
- 572 20. Chomarat M, Breyse F. Technique d'analyse des courbes de fusion haute résolution
573 (FHR) ou High Resolution Melting analysis (HRM) en infectiologie. *Immuno-Anal Biol Spe*
574 2011; **26**(4): 207-11.
- 575 21. Schneider ZD, Shah MP, Boily MC, et al. Mass Drug Administration to Reduce Malaria
576 Transmission: A Systematic Review and Meta-Analysis. *Am J Trop Med* 2023: tpm220766-
577 tpm2.
- 578 22. Malaria Policy Advisory Committee. Meeting report of the Evidence Review Group on
579 mass drug administration, mass screening and treatment and focal screening and treatment for
580 malaria (20–22 April 2015). Geneva, Switzerland, 2015.
- 581 23. Dabira ED, Soumare HM, Conteh B, et al. Mass drug administration of ivermectin and
582 dihydroartemisinin–piperaquine against malaria in settings with high coverage of standard
583 control interventions: a cluster-randomised controlled trial in The Gambia. *Lancet Infect Dis*
584 2022; **22**(4): 519-28.
- 585 24. Rek J, Blanken SL, Okoth J, et al. Asymptomatic school-aged children are important
586 drivers of malaria transmission in a high endemicity setting in Uganda. *J Infect Dis* 2022; **226**(4):
587 708-13.
- 588


589 **Figures**

Figure 1. Timeline of study activities




Abbreviations: MDA = mass drug administration; PBO = piperonyl butoxide; PECADOM+ = Prise en Charge à Domicile Plus (i.e., proactive community case management of malaria); SMC = seasonal malaria chemoprevention

590 **Figure 2.** Trial profile



Abbreviations: HP = health post; MDA = mass drug administration; PEACDOM+ = Prise en Charge à Domicile Plus (i.e., proactive community case management of malaria); SMC = seasonal malaria chemoprevention

591 **Figure 3.** Graphical representation of village-level monthly incidence of symptomatic malaria
 592 during the intervention implementation year by intervention group (A) and stratified by age
 593 group (B), and baseline transmission intensity (C).



Abbreviations: MDA = mass drug administration; SMC = seasonal malaria chemoprevention
 Monthly incidence rates and corresponding 95% confidence intervals, represented by points and bars, respectively, were calculated using a random effects Poisson model with village-level random intercepts to account for clustered observations.

594 **Tables**

595 **Table 1.** Trial profile

Characteristics	Total	Intervention (MDA)	Control
Village-level¹			
Number of clusters (villages)	60	30	30
Villages by health post, n (%)			
Bohe	9 (15%)	6 (20%)	3 (10%)
Dar Salam	2 (3%)	1 (3%)	1 (3%)
Dawadi	14 (23%)	6 (20%)	8 (27%)
Koussanar	9 (15%)	5 (17%)	4 (13%)
Missirah	6 (10%)	2 (7%)	4 (13%)
Neteboulou	5 (8%)	2 (7%)	3 (10%)
Sinthiou Maleme	15 (25%)	8 (27%)	7 (23%)
Presence of DSDOM prior to the study, n (%)			
No	20 (33%)	10 (33%)	10 (33%)
Yes	40 (67%)	20 (67%)	20 (67%)
Distance to health post in km, mean (SD)	14.8 (8.4)	14.9 (8.6)	14.6 (8.3)
Population size in 2019 ² , mean (SD)	322 (168)	330 (170)	315 (168)
Population size <10 years of age in 2019 ² , mean (SD)	119 (62)	120 (63)	117 (62)
% Population <10 years of age in 2019, mean (SD)	37% (5)	36% (4)	37% (6)
Baseline microscopy prevalence (%), mean (SD)	8% (8)	7% (9)	9% (8)
Individual-level Characteristics from Baseline Survey, n (%)			
Participant age in years			
<10 years of age	783 (33%)	373 (32%)	410 (35%)
≥10 years of age	1578 (67%)	809 (68%)	769 (65%)
Participant sex			
Male	1180 (50%)	576 (49%)	604 (51%)
Female	1182 (50%)	607 (51%)	575 (49%)
Slept away from home in the past 15 days			
Yes	459 (20%)	245 (21%)	214 (19%)
No	1846 (80%)	910 (79%)	936 (81%)
Type of bed net used			
None	37 (2%)	28 (2%)	9 (1%)
Pyrethroid-PBO ITN	2282 (98%)	1131 (96%)	1151 (99%)
Non-pyrethroid-PBO ITN	21 (1%)	20 (2%)	1 (0.1%)
Received the most recent cycle of SMC? ³			
No	169 (20%)	94 (23%)	75 (17%)
Yes	687 (81%)	316 (77%)	371 (83%)
Completed all three cycles of SMC in 2020? ³			
No	248 (29%)	128 (31%)	120 (27%)
Yes	610 (71%)	284 (69%)	326 (73%)

Abbreviations: ITN = insecticide-treated net; MDA = mass drug administration; PBO = piperonyl butoxide; SD = standard deviation; SMC = seasonal malaria chemoprevention

¹ Village-level variables used in constrained randomization scheme.

² Incidence estimates provided by Tambacounda Regional District Office.

³ Assessed only among children <10 years of age.

596 **Table 2.** RDT-confirmed malaria incidence and intervention effectiveness estimates during peak transmission season (July-December)

Study outcomes	Average incidence per 1,000 (events / population)				Intervention effect, 1-ratio of IRRs [95% CI] ¹	
	Intervention (MDA)		Control		Unadjusted	Adjusted ²
	2020	2021	2020	2021		
Primary outcome						
Incidence among all ages	181 (2067/10745)	93 (924/10745)	204 (1883/9641)	173 (1751/9641)	52% [21%, 71%]	55% [28%, 72%]
<10 years old	133 (514/4091)	84 (287/4091)	154 (515/3598)	120 (463/3598)	43% [3%, 66%]	46% [10%, 67%]
≥10 years and older	213 (1553/6637)	100 (633/6637)	236 (1368/5991)	206 (1287/5991)	55% [27%, 73%]	58% [33%, 74%]
Subgroup analyses						
Among children <10 years of age						
<5 years of age	102 (163/1939)	69 (115/1939)	133 (208/1723)	93 (166/1723)	29% [-35%, 62%]	31% [-25%, 62%]
5 to <10 years of age	85 (351/2152)	61 (172/2152)	118 (307/1875)	85 (297/1875)	43% [-4%, 69%]	45% [4%, 68%]
Baseline transmission intensity ³						
Low (<10%)	172 (1508/8316)	83 (658/8316)	228 (1385/6463)	171 (1085/6463)	53% [25%, 71%]	55% [31%, 71%]
Moderate (≥10%)	214 (559/2429)	125 (266/2429)	148 (498/3178)	178 (666/3178)	49% [-48%, 82%]	52% [-19%, 81%]

Abbreviations: IRR = incidence rate ratio; MDA = mass drug administration

¹ Intervention effect estimated using mixed effects Poisson regression with village-level random intercepts.

² Adjusted for DSDOM at baseline, village population size of children <10 years of age, distance from health post, baseline parasite prevalence by microscopy, and village population size in 2019, and presence of DSDOM at time of case detection.

³ Transmission intensity was defined as baseline village-level microscopy-confirmed parasite prevalence of <10% for “Low” transmission clusters and ≥10% for “Moderate” transmission clusters. 23 clusters from the intervention arm and 21 clusters from the control arm contributed to “Low” category; 7 clusters in intervention arm and 9 clusters in control arm contributed to “Moderate” category.

597 **Table 3.** Secondary outcomes of parasite prevalence.

Outcomes	Mean prevalence, % [95% CI] ¹				Intervention effect, 1-ratio of PRs [95% CI] ¹	
	Intervention (MDA)		Control		Unadjusted	Adjusted ²
	2020	2021	2020	2021		
Microscopy-detected infections						
All ages	6.1% [2.8%, 9.4%]	1.8% [0.8%, 2.9%]	6.7% [4.0%, 9.4%]	4.7% [2.5%, 6.9%]	61% [21%, 81%]	62% [22%, 80%]
< 10 years old	8.2% [2.7%, 13.7%]	1.3% [0.2%, 2.4%]	7.3% [3.1%, 11.6%]	4.5% [2.0%, 7.0%]	76% [41%, 90%]	76% [42%, 90%]
≥ 10 years and older	5.1% [2.6%, 7.7%]	2.2% [0.7%, 3.6%]	6.4% [3.9%, 8.8%]	4.8% [1.8%, 7.9%]	50% [-16%, 79%]	51% [-14%, 79%]
Baseline transmission intensity ³						
Low (<10%)	2.6% [1.3%, 3.9%]	1.0% [0.2%, 1.8%]	3.4% [2.1%, 4.8%]	4.3% [1.4%, 7.2%]	63% [-1%, 86%]	62% [0%, 86%]
Moderate (≥10%)	18.8% [9.4%, 28.2%]	5.0% [2.1%, 7.8%]	17.1% [12.5%, 21.8%]	6.0% [3.4%, 8.6%]	54% [18%, 73%]	56% [22%, 75%]
PCR-detected infections						
All ages	17.9% [11.3%, 24.4%]	4.5% [2.5%, 6.4%]	19.9% [11.8%, 28.1%]	8.3% [4.8%, 11.7%]	46% [-3%, 70%]	47% [3%, 71%]
< 10 years old	18.6% [10.9%, 26.4%]	2.3% [0.6%, 3.9%]	19.6% [9.9%, 29.4%]	5.1% [2.2%, 8.0%]	71% [34%, 87%]	71% [35%, 87%]
≥ 10 years and older	17.5% [11.0%, 24.0%]	5.8% [2.9%, 8.6%]	20.1% [11.7%, 28.5%]	10.2% [5.2%, 15.3%]	33% [-27%, 64%]	33% [-27%, 65%]
Baseline transmission intensity ³						
Low (<10%)	14.0% [7.9%, 20.1%]	3.0% [1.0%, 5.0%]	14.3% [6.3%, 22.3%]	4.7% [2.4%, 6.9%]	48% [-4%, 74%]	47% [-7%, 74%]
Moderate (≥10%)	32.0% [11.4%, 52.5%]	9.9% [6.1%, 13.7%]	38.0% [21.7%, 54.4%]	18.7% [12.2%, 25.3%]	37% [2%, 59%]	40% [9%, 60%]

Abbreviations: MDA = mass drug administration; PCR = polymerase chain reaction; PR = prevalence ratio

¹ Intervention effect estimated using Poisson regression with robust standard errors. Survey weights incorporated to account for two-stage sampling design (by household and household size).

² Adjusted for variables included in constrained randomisation: presence of DSDOM at baseline, village population size of children <10 years of age, distance from health post, and village population size in 2019.

³ Transmission intensity was defined as baseline village-level microscopy-confirmed parasite prevalence of <10% for “Low” transmission clusters and ≥10% for “Moderate” transmission clusters. 23 clusters from the intervention arm and 21 clusters from the control arm contributed to “Low” category; 7 clusters in intervention arm and 9 clusters in control arm contributed to “Moderate” category.

598 **Table 4.** Safety outcomes monitored through active surveillance.

Active Surveillance	Intervention (MDA)	Control (SMC)	p-value ¹
Among all participants surveyed			
Participants with any AE, n/N (%)			
All cycles	260/1903 (13.7%)	152/1616 (9.4%)	<0.0001
First cycle	124/619 (20.0%)	93/569 (16.3%)	0.10
Second cycle	94/628 (15.0%)	51/563 (9.1%)	0.002
Third cycle	42/656 (6.4%)	8/484 (1.7%)	<0.0001
Frequency of adverse events, n			
All cycles	498	310	--
First cycle	229	175	--
Second cycle	181	119	--
Third cycle	88	16	--
Most common adverse events, n/N (%)			
Gastrointestinal issues ²	205/498 (41.2%)	144/310 (46.5%)	0.16
Fever	113/498 (22.7%)	109/310 (35.2%)	<0.001
Headaches	59/498 (11.8%)	20/310 (6.5%)	0.017
Drowsiness	26/498 (5.2%)	8/310 (2.6%)	0.102
Other	95/498 (19.1%)	29/310 (9.4%)	<0.001
Severity of AEs, n/N (%)			
Mild	319/498 (64.1%)	178/310 (57.4%)	0.059
Moderate	164/498 (32.9%)	118/310 (38.1%)	0.14
Severe	15/498 (3.0%)	14/310 (4.5%)	0.26
Any serious AE, n/N (%)	0/498 (0%)	0/310 (0%)	--
Among children <10 years of age			
Participants with any AE, n/N (%)			
All cycles	85/841 (10.1%)	145/1544 (9.4%)	0.57
First cycle	36/259 (13.9%)	90/547 (16.5%)	0.35
Second cycle	33/271 (12.2%)	47/529 (8.9%)	0.14
Third cycle	16/311 (5.1%)	8/468 (1.7%)	0.007
Frequency of adverse events, n			
All cycles	176	296	--
First cycle	68	170	--
Second cycle	67	110	--
Third cycle	41	16	--
Most common adverse events, n/N (%)			
Gastrointestinal issues ²	87/176 (49.4%)	136/296 (45.9%)	0.523
Fever	50/176 (28.4%)	106/296 (35.8%)	0.121
Headache	10/176 (5.7%)	19/296 (6.4%)	0.901
Drowsiness	2/176 (1.1%)	8/296 (2.7%)	0.334
Other	27/176 (15.3%)	27/296 (9.1%)	0.0057
Severity of AEs, n/N (%)			
Mild	102/176 (58.0%)	169/296 (57.1%)	0.86
Moderate	69/176 (39.2%)	115/296 (38.9%)	0.94
Severe	5/176 (2.8%)	12/296 (4.1%)	0.49
Any serious AE, n/N (%)	0/176 (0%)	0/296 (0%)	--

Abbreviations: AE = adverse event

¹ P-value computed using Chi-squared test or Fisher's exact test (if frequency of any cell value was <5)

² Defined as one of the following AEs: nausea, vomiting, diarrhoea, abdominal pain, or loss of appetite.